These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20362408)

  • 21. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
    Perry CM; Jarvis B
    BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    Ferenci P
    Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
    Keam SJ; Cvetković RS
    BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.
    Plosker GL; Keating GM
    Drugs; 2004; 64(24):2823-43. PubMed ID: 15563253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
    McHutchison JG; Lawitz EJ; Shiffman ML; Muir AJ; Galler GW; McCone J; Nyberg LM; Lee WM; Ghalib RH; Schiff ER; Galati JS; Bacon BR; Davis MN; Mukhopadhyay P; Koury K; Noviello S; Pedicone LD; Brass CA; Albrecht JK; Sulkowski MS;
    N Engl J Med; 2009 Aug; 361(6):580-93. PubMed ID: 19625712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Keating GM; Curran MP
    Drugs; 2003; 63(7):701-30. PubMed ID: 12656650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
    Dimitroulopoulos D; Petroulaki E; Manolakopoulos S; Anagnostou O; Tsaklakidou D; Xinopoulos D; Tsamakidis K; Tzourmakliotis D; Paraskevas E
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1407-12. PubMed ID: 19916203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.
    Alvarez-Uria G; Day JN; Nasir AJ; Russell SK; Vilar FJ
    Liver Int; 2009 Aug; 29(7):1051-5. PubMed ID: 19580634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
    Giguere A; Anas A; Nasser T; Hassan MH; Ahmed U; Beejay N; Nouh M; Khalowf M; Saleh A; Khan A; Attia M; El-Azab G
    Eur J Intern Med; 2011 Dec; 22(6):582-6. PubMed ID: 22075284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
    Sasadeusz JJ; Dore G; Kronborg I; Barton D; Yoshihara M; Weltman M
    Addiction; 2011 May; 106(5):977-84. PubMed ID: 21205057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Schaefer M; Mauss S
    Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation.
    Zwirtes R; Narasimhan P; Wind-Rotolo MM; Xu D; Hruska MW; Kishnani N; Colston EM; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):644-651. PubMed ID: 27710263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].
    Ruzić M; Milotka F; Klasnja B; Pobor M; Svarc D; Jovelic A; Fabri I
    Srp Arh Celok Lek; 2010; 138(1-2):43-9. PubMed ID: 20425908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Short-term treatment of Hepatitis C in heroin-dependent patients].
    Kristensen Ø; Sundøy A; Skeie K; Vederhus JK; Øye I; Opsal A; Rysstad O; Gallefoss F
    Tidsskr Nor Laegeforen; 2009 Aug; 129(16):1639-42. PubMed ID: 19721480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
    Morsy KH; Zaghloul A; Mahmoud M
    Turk J Gastroenterol; 2016 Jan; 27(1):55-61. PubMed ID: 26674982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease.
    Ayyub MA; El-Moursy SA; Khazindar AM; Abbas FA
    Saudi Med J; 2009 May; 30(5):712-6. PubMed ID: 19417977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
    Rajender Reddy K; Modi MW; Pedder S
    Adv Drug Deliv Rev; 2002 Jun; 54(4):571-86. PubMed ID: 12052715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.